Please assess the completion status of the following clinical trial:

Trial Title: The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged between 18 and 65 years, inclusive.~* Subjects who were on an established regimen of phenytoin monotherapy, which had been stable for at least 3 months.~* Subjects who had clinical laboratory tests acceptable to the Investigator.~* Subjects who were negative for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (Ab) and human immunodeficiency viruses (HIV-1 and HIV-2) Ab tests at screening.~* Subjects who were negative for alcohol and drugs of abuse at screening.~* Subjects who were non-smokers or who smoked less than 10 cigarettes or equivalent per day.~* Subjects who were able and willing to gave written informed consent.~* (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device.~* (If female) She had a negative pregnancy test at screening.~Exclusion Criteria:~* Subjects who did not conform to the above inclusion criteria.~* Subjects who had a clinically relevant history or presence of any disease that may interfere with the pharmacokinetics or pharmacodynamics of the Investigational Products, or may affect its safety.~* Subjects who had a history of relevant drug hypersensitivity.~* Subjects who had a history of alcoholism or drug abuse in the last 2 years.~* Subjects who consumed more than 21 units of alcohol a week.~* Subjects who had one of the following findings on the electrocardiogram (ECG): sinus bradycardia, sinoatrial block, atrioventricular block of any degree.~* Subjects who had a significant infection or known inflammatory process on screening and/or admission.~* Subjects who had acute gastrointestinal symptoms at the time of screening and/or admission (e.g., nausea, vomiting, diarrhoea, heartburn).~* Subjects who had used any drugs (other than phenytoin) that may affect the pharmacokinetic profile of the investigational products within 2 weeks of first dosing.~* Subjects who had used any investigational drug and/or participated in any clinical trial within 3 months of their first admission to this study.~* Subjects who had previously received ESL.~* Subjects who had donated and/or received any blood or blood products within the previous 3 months prior to screening.~* Subjects who were vegetarians, vegans and/or have medical dietary restrictions.~* Subjects who cannot communicate reliably with the investigator.~* Subjects who were unlikely to co-operate with the requirements of the study.~* Subjects who were unwilling or unable to gave written informed consent.~* (If female) She was pregnant or breast-feeding.~* (If female) She was of childbearing potential and she did not use an approved effective contraceptive method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eslicarbazepine acetate (Type: EXPERIMENTAL): ESL 600 mg tablets
- phenytoin (Type: ACTIVE_COMPARATOR): Hidantina® 100 mg tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).